| Rai, Prichard et al. 2011 [23] | USA | Quasi 1 group pre post | Async | MCC | 2 | Quality, Utilization |
| 55.00 |
|
| 24.00 | Positive |
| Vinson, McCallum et al. 2011 [24] | USA | OBS 1 group | Mixed | Diabetes | 1 | Quality |
|
|
|
| 12.00 | Positive |
| Gellis, Kenaley et al. 2012 [25] | USA | RCT | RPM | MCC | 6 | Efficacy, Quality |
| 62.10 | Urban | 80.1 | 12.00 | Positive |
| Akematsu and Tsuji 2012 [26] | Japan | Quasi 2 group | Mixed | MCC | 4 | Cost, Utilization |
| 40.90 | Rural | 75 | 520.00 | Positive |
| Steventon, Bardsley et al. 2012 [27] | UK & USA | RCT | Mixed | MCC | 3 | Utilization |
|
|
| 69.7 | 24.00 | Positive |
| Jaglal, Haroun et al. 2013 [28] | Canada | Quasi 2 group | Sync | MCC | 6 | Efficacy |
| 74.20 | Rural | 67 | 6.00 | Positive |
| Balato, Megna et al. 2013 [29] | Italy | Quasi 1 group pre post | Async | Psoriasis | 1 | Adherence, Efficacy, Quality |
| 50.00 |
|
| 12.00 | Positive |
| Baker, Macaulay et al. 2013 [30] | USA | Retrospective 2 group | RPM | MCC | 3 | Efficacy, Quality, Utilization |
| 46.30 |
| 76 | 104.00 | Positive |
| Chung, Kim et al. 2013 [31] | USA | Quasi 1 group pre post | Mixed | MCC | 3 | Efficacy | 65.00 | 63.00 | Urban | 59 | 8.00 | Neutral |
| Surate Solaligue, Hederman et al. 2014 [32] | Ireland | Quasi 1 group pre post | Mixed | MCC | 6 | Utilization |
|
|
|
| 52.00 | Neutral |
| Cecil 2014 [33] | USA | Retrospective | Sync | MS | 1 | Utilization | 25.00 | 75.00 |
| 50.1 | 416.00 | Positive |
| Gellis, Kenaley et al. 2014 [34] | USA | RCT | Mixed | MCC | 2 | Efficacy, Utilization |
|
|
| 79 | 12.00 | Positive |
| Hui-Lung, Chung-Hung et al. 2015 [35] | Taiwan | Quasi 1 group pre post | Mixed | MCC | 5 | Efficacy |
| 56.00 | Rural |
|
| Positive |
| Leboeuf-Yde, Jensen et al. 2015 [36] | Denmark | Quasi 1 group pre post | Async | Back Pain | 1 | Efficacy |
|
|
|
| 52.00 | Neutral |
| Chatwin, Hawkins et al. 2016 [37] | UK | RCT crossover | RPM | Lung disease | 5 | Utilization |
|
| Urban | 61.8 | 24.00 | Negative |
| Doñate-Martínez, Ródenas et al. 2016 [38] | Spain | Descriptive | RPM | MCC | 4 | Efficacy, Quality |
|
|
| 67.95 | 52.00 | Positive |
| Gonçalves, Ciol et al. 2016 [39] | Brazil | RCT | Sync | Burns | 1 | Efficacy |
|
| Urban | 40.4 | 24.00 | Positive |
| Kekäle, Söderlund et al. 2016 [40] | Finland | RCT | Mixed | Chronic myeloid leukemia | 1 | Adherence |
| 50.00 |
| 58.3 | 36.00 | Positive |
| Schougaard, Larsen et al. 2016 [41] | Denmark | OBS 1 group | RPM | MCC | 1 | Utilization |
|
|
|
| 84.00 | Positive |
| Hamad, Crooks et al. 2016 [42] | UK | OBS 1 group | RPM | COPD | 1 | Efficacy, Utilization |
| 51.90 |
| 69.5 | 16.00 | Positive |
| Dhillon, Wünsche et al. 2016 [43] | Malaysia | Quasi 1 group pre post | Mixed | MCC | 1 | Quality |
|
|
| 79 | 6.00 | Positive |